Share Price and Basic Stock Data
Last Updated: February 2, 2026, 5:18 pm
| PEG Ratio | -4.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Emmessar Biotech & Nutrition Ltd operates within the Chemicals – Inorganic – Others sector, with its stock currently priced at ₹27.7 and a market capitalization of ₹13.9 Cr. The company has demonstrated fluctuating revenue trends over recent quarters. Sales were reported at ₹0.07 Cr in September 2022, increasing to ₹0.43 Cr by December 2022. However, sales then declined to ₹0.32 Cr in March 2023, and further dropped to ₹0.07 Cr in June 2023. A slight recovery was noted with sales at ₹0.08 Cr in September 2023, followed by ₹0.33 Cr in December 2023. The trailing twelve months (TTM) revenue stands at ₹0.38 Cr, indicating challenges in maintaining consistent sales momentum. Historical annual sales figures also reflect volatility, peaking at ₹6.99 Cr in March 2021, but falling to ₹0.36 Cr in March 2022 before recovering slightly to ₹1.02 Cr in March 2023. This inconsistency raises concerns regarding the company’s operational stability and market demand for its products.
Profitability and Efficiency Metrics
Emmessar’s profitability metrics reveal significant challenges, highlighted by an operating profit margin (OPM) of -411.11% as of September 2025. This negative margin reflects a persistent inability to cover operational expenses, which stood at ₹0.46 Cr in the same period. The company’s net profit for the trailing twelve months was ₹0.23 Cr, with a net profit margin of just 51.75% in March 2025, indicating a precarious profitability position. The return on equity (ROE) is reported at 4.23%, while return on capital employed (ROCE) stands at 12.6%, both of which are relatively low compared to industry benchmarks. Furthermore, the cash conversion cycle (CCC) has extended to 242.49 days, suggesting inefficiencies in managing working capital. The company recorded a negative operating profit in most recent quarters, further emphasizing the operational challenges it faces.
Balance Sheet Strength and Financial Ratios
The balance sheet of Emmessar Biotech reflects a solid foundation with zero borrowings reported, indicating a conservative financing approach. The reserves have shown a gradual increase, reaching ₹3.00 Cr by September 2025, up from ₹1.67 Cr in March 2023. The company’s current ratio is exceptionally high at 15.67, suggesting robust liquidity and an ability to cover short-term liabilities. The price-to-book value (P/BV) ratio stands at 1.97x, indicating that the stock is trading at a premium relative to its book value. The interest coverage ratio (ICR) is remarkably high at 1760.67x, signaling that the company is well-positioned to meet its interest obligations. However, the asset turnover ratio at 0.06 indicates inefficiencies in converting assets into revenue, which could hinder growth potential. Overall, while the balance sheet shows strength in liquidity and lack of debt, operational inefficiencies remain a concern.
Shareholding Pattern and Investor Confidence
Emmessar Biotech’s shareholding pattern reveals a stable promoter holding of 59.53% as of September 2025, which indicates a strong commitment from the management. The public holds 40.28%, while foreign institutional investors (FIIs) are not reported, suggesting limited external institutional interest. Domestic institutional investors (DIIs) account for a minor 0.19%, reflecting low confidence from institutional investors in the company’s growth prospects. The number of shareholders has increased to 7,350 as of September 2025, up from 7,024 in December 2022, indicating a slight rise in retail investor interest despite the company’s operational challenges. The consistent promoter holding alongside a gradual increase in shareholder numbers may imply potential long-term investor confidence, but the overall low institutional presence could be a red flag for market perception.
Outlook, Risks, and Final Insight
Looking ahead, Emmessar Biotech faces both opportunities and risks. The absence of debt provides a cushion against financial strain, while the high liquidity can facilitate operational improvements. However, the company’s historical volatility in sales and profitability metrics pose significant risks to its sustainability. Operational inefficiencies, as indicated by the prolonged cash conversion cycle and negative operating profits, need urgent attention for any turnaround strategy to be effective. The low institutional interest may limit capital inflow for growth initiatives. Should the company enhance operational efficiency and stabilize its revenue streams, it could leverage its financial strengths to improve market positioning. Conversely, failure to address these challenges may lead to continued instability and reduced investor confidence, impacting future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,370 Cr. | 36.5 | 125/33.1 | 59.9 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 13.3 Cr. | 26.7 | 42.9/24.3 | 58.0 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 219 Cr. | 279 | 356/236 | 13.0 | 211 | 2.87 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 7,060 Cr. | 572 | 728/408 | 34.4 | 157 | 0.52 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 339 Cr. | 433 | 503/376 | 14.3 | 144 | 0.69 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 4,706.13 Cr | 374.78 | 114.26 | 156.25 | 0.49% | 13.95% | 10.65% | 6.18 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.07 | 0.43 | 0.32 | 0.07 | 0.08 | 0.33 | 0.08 | 0.08 | 0.34 | 0.10 | 0.10 | 0.09 | 0.09 |
| Expenses | 0.27 | 0.60 | 0.48 | 0.35 | 0.30 | 0.54 | 0.47 | 0.36 | 0.42 | 0.38 | 0.43 | 0.36 | 0.46 |
| Operating Profit | -0.20 | -0.17 | -0.16 | -0.28 | -0.22 | -0.21 | -0.39 | -0.28 | -0.08 | -0.28 | -0.33 | -0.27 | -0.37 |
| OPM % | -285.71% | -39.53% | -50.00% | -400.00% | -275.00% | -63.64% | -487.50% | -350.00% | -23.53% | -280.00% | -330.00% | -300.00% | -411.11% |
| Other Income | 0.43 | 0.44 | 0.42 | 0.46 | 0.53 | 0.53 | 0.48 | 0.46 | 0.51 | 0.43 | 0.61 | 0.53 | 0.54 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 |
| Profit before tax | 0.21 | 0.25 | 0.24 | 0.16 | 0.29 | 0.30 | 0.07 | 0.16 | 0.41 | 0.13 | 0.26 | 0.24 | 0.14 |
| Tax % | 33.33% | 108.00% | 20.83% | 68.75% | 31.03% | 56.67% | -285.71% | 43.75% | 31.71% | 84.62% | 126.92% | 25.00% | 21.43% |
| Net Profit | 0.13 | -0.02 | 0.20 | 0.05 | 0.20 | 0.13 | 0.27 | 0.09 | 0.28 | 0.02 | -0.07 | 0.17 | 0.11 |
| EPS in Rs | 0.26 | -0.04 | 0.40 | 0.10 | 0.40 | 0.26 | 0.54 | 0.18 | 0.56 | 0.04 | -0.14 | 0.34 | 0.22 |
Last Updated: December 27, 2025, 3:05 am
Below is a detailed analysis of the quarterly data for Emmessar Biotech & Nutrition Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.09 Cr..
- For Expenses, as of Sep 2025, the value is 0.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.36 Cr. (Jun 2025) to 0.46 Cr., marking an increase of 0.10 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.37 Cr.. The value appears to be declining and may need further review. It has decreased from -0.27 Cr. (Jun 2025) to -0.37 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Sep 2025, the value is -411.11%. The value appears to be declining and may need further review. It has decreased from -300.00% (Jun 2025) to -411.11%, marking a decrease of 111.11%.
- For Other Income, as of Sep 2025, the value is 0.54 Cr.. The value appears strong and on an upward trend. It has increased from 0.53 Cr. (Jun 2025) to 0.54 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Jun 2025) to 0.03 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.14 Cr.. The value appears to be declining and may need further review. It has decreased from 0.24 Cr. (Jun 2025) to 0.14 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Sep 2025, the value is 21.43%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Jun 2025) to 21.43%, marking a decrease of 3.57%.
- For Net Profit, as of Sep 2025, the value is 0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.17 Cr. (Jun 2025) to 0.11 Cr., marking a decrease of 0.06 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.22. The value appears to be declining and may need further review. It has decreased from 0.34 (Jun 2025) to 0.22, marking a decrease of 0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:47 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.37 | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.38 |
| Expenses | 1.43 | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | 1.63 |
| Operating Profit | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.64 | -0.41 | 0.84 | -0.90 | -0.69 | -1.08 | -0.95 | -1.25 |
| OPM % | -4.38% | -6.85% | -34.34% | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% | -328.95% |
| Other Income | 0.09 | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | 2.11 |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.20 | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.10 | 0.09 |
| Profit before tax | -0.17 | -0.16 | -0.68 | 1.19 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 | 0.77 |
| Tax % | 82.35% | -25.00% | -30.88% | 0.00% | -15.00% | -82.76% | -2.70% | 36.00% | 48.39% | 47.42% | 7.41% | 66.67% | |
| Net Profit | -0.31 | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 | 0.32 | 0.23 |
| EPS in Rs | -0.62 | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 61.29% | -291.67% | 353.19% | -23.53% | -41.76% | 41.51% | 93.33% | -66.90% | 4.17% | 50.00% | -57.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -352.96% | 644.86% | -376.72% | -18.23% | 83.27% | 51.82% | -160.23% | 71.06% | 45.83% | -107.33% |
Emmessar Biotech & Nutrition Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -29% |
| 3 Years: | 19% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -20% |
| 3 Years: | -13% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 15% |
| 3 Years: | 2% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:21 pm
Balance Sheet
Last Updated: February 1, 2026, 4:45 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves | -3.42 | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.71 | 3.00 |
| Borrowings | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.07 | -0.00 | -0.00 | -0.00 | 0.08 | 0.11 | -0.00 | -0.00 |
| Other Liabilities | 0.65 | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.51 | 1.52 |
| Total Liabilities | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 | 9.52 |
| Fixed Assets | 1.58 | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.81 | 1.77 |
| CWIP | -0.00 | -0.00 | -0.00 | 0.80 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 0.64 | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.40 | 7.74 |
| Total Assets | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 | 9.52 |
Below is a detailed analysis of the balance sheet data for Emmessar Biotech & Nutrition Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.71 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 0.29 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.51 Cr. (Mar 2025) to 1.52 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.22 Cr. (Mar 2025) to 9.52 Cr., marking an increase of 0.30 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1.77 Cr.. The value appears to be declining and may need further review. It has decreased from 1.81 Cr. (Mar 2025) to 1.77 Cr., marking a decrease of 0.04 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Other Assets, as of Sep 2025, the value is 7.74 Cr.. The value appears strong and on an upward trend. It has increased from 7.40 Cr. (Mar 2025) to 7.74 Cr., marking an increase of 0.34 Cr..
- For Total Assets, as of Sep 2025, the value is 9.52 Cr.. The value appears strong and on an upward trend. It has increased from 9.22 Cr. (Mar 2025) to 9.52 Cr., marking an increase of 0.30 Cr..
Notably, the Reserves (3.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.71 | -0.41 | 0.84 | -0.90 | -0.77 | -1.19 | -0.95 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45.29 | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 | 11.97 |
| Inventory Days | 267.67 | 335.80 | 136.88 | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 | 230.53 |
| Days Payable | 121.67 | 150.87 | 76.04 | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 | 0.00 |
| Cash Conversion Cycle | 191.29 | 191.60 | 127.20 | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 | 242.49 |
| Working Capital Days | 29.31 | 38.33 | 22.12 | 85.31 | 175.31 | 457.70 | 30.06 | 79.37 | -60.83 | 114.51 | 91.25 | 35.90 |
| ROCE % | -9.60% | -10.81% | -39.30% | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.61 | 1.48 | 0.99 | 0.94 | 2.88 |
| Diluted EPS (Rs.) | 0.61 | 1.48 | 0.99 | 0.94 | 2.88 |
| Cash EPS (Rs.) | 0.82 | 1.70 | 1.20 | 1.14 | 3.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 |
| Revenue From Operations / Share (Rs.) | 1.22 | 1.11 | 2.04 | 0.73 | 13.99 |
| PBDIT / Share (Rs.) | 2.11 | 1.82 | 2.12 | 2.05 | 4.63 |
| PBIT / Share (Rs.) | 1.92 | 1.63 | 1.94 | 1.86 | 4.51 |
| PBT / Share (Rs.) | 1.92 | 1.63 | 1.94 | 1.86 | 4.51 |
| Net Profit / Share (Rs.) | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 |
| PBDIT Margin (%) | 172.92 | 163.94 | 104.05 | 280.54 | 33.07 |
| PBIT Margin (%) | 156.94 | 146.36 | 94.86 | 255.24 | 32.25 |
| PBT Margin (%) | 156.85 | 146.36 | 94.86 | 255.24 | 32.25 |
| Net Profit Margin (%) | 51.75 | 135.01 | 49.43 | 130.25 | 20.73 |
| Return on Networth / Equity (%) | 4.10 | 10.12 | 7.55 | 7.70 | 25.43 |
| Return on Capital Employeed (%) | 10.96 | 9.86 | 12.85 | 13.53 | 35.20 |
| Return On Assets (%) | 3.42 | 8.57 | 6.34 | 6.58 | 18.57 |
| Total Debt / Equity (X) | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.06 | 0.06 | 0.13 | 0.04 | 1.00 |
| Current Ratio (X) | 15.67 | 13.56 | 14.14 | 14.73 | 3.85 |
| Quick Ratio (X) | 15.41 | 13.38 | 13.82 | 14.52 | 3.80 |
| Inventory Turnover Ratio (X) | 5.74 | 0.56 | 0.67 | 0.24 | 4.14 |
| Interest Coverage Ratio (X) | 1760.67 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 528.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 8.31 | 8.78 | 7.28 | 9.16 | 4.87 |
| EV / Net Operating Revenue (X) | 13.61 | 15.81 | 7.14 | 25.09 | 0.69 |
| EV / EBITDA (X) | 7.87 | 9.64 | 6.87 | 8.94 | 2.11 |
| MarketCap / Net Operating Revenue (X) | 24.85 | 26.74 | 12.16 | 37.65 | 1.05 |
| Price / BV (X) | 1.97 | 2.01 | 1.86 | 2.23 | 1.29 |
| Price / Net Operating Revenue (X) | 24.87 | 26.75 | 12.16 | 37.67 | 1.05 |
| EarningsYield | 0.02 | 0.05 | 0.04 | 0.03 | 0.19 |
After reviewing the key financial ratios for Emmessar Biotech & Nutrition Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 1.48 (Mar 24) to 0.61, marking a decrease of 0.87.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 1.48 (Mar 24) to 0.61, marking a decrease of 0.87.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 3. It has decreased from 1.70 (Mar 24) to 0.82, marking a decrease of 0.88.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.43. It has increased from 14.82 (Mar 24) to 15.43, marking an increase of 0.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.43. It has increased from 14.82 (Mar 24) to 15.43, marking an increase of 0.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1.22. It has increased from 1.11 (Mar 24) to 1.22, marking an increase of 0.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 1.82 (Mar 24) to 2.11, marking an increase of 0.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.92, marking an increase of 0.29.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.92, marking an increase of 0.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 2. It has decreased from 1.50 (Mar 24) to 0.63, marking a decrease of 0.87.
- For PBDIT Margin (%), as of Mar 25, the value is 172.92. This value is within the healthy range. It has increased from 163.94 (Mar 24) to 172.92, marking an increase of 8.98.
- For PBIT Margin (%), as of Mar 25, the value is 156.94. This value exceeds the healthy maximum of 20. It has increased from 146.36 (Mar 24) to 156.94, marking an increase of 10.58.
- For PBT Margin (%), as of Mar 25, the value is 156.85. This value is within the healthy range. It has increased from 146.36 (Mar 24) to 156.85, marking an increase of 10.49.
- For Net Profit Margin (%), as of Mar 25, the value is 51.75. This value exceeds the healthy maximum of 10. It has decreased from 135.01 (Mar 24) to 51.75, marking a decrease of 83.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 15. It has decreased from 10.12 (Mar 24) to 4.10, marking a decrease of 6.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.96. This value is within the healthy range. It has increased from 9.86 (Mar 24) to 10.96, marking an increase of 1.10.
- For Return On Assets (%), as of Mar 25, the value is 3.42. This value is below the healthy minimum of 5. It has decreased from 8.57 (Mar 24) to 3.42, marking a decrease of 5.15.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.06. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Current Ratio (X), as of Mar 25, the value is 15.67. This value exceeds the healthy maximum of 3. It has increased from 13.56 (Mar 24) to 15.67, marking an increase of 2.11.
- For Quick Ratio (X), as of Mar 25, the value is 15.41. This value exceeds the healthy maximum of 2. It has increased from 13.38 (Mar 24) to 15.41, marking an increase of 2.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.74. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 5.74, marking an increase of 5.18.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,760.67. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 1,760.67, marking an increase of 1,760.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 528.00. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 528.00, marking an increase of 528.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.31. It has decreased from 8.78 (Mar 24) to 8.31, marking a decrease of 0.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has decreased from 15.81 (Mar 24) to 13.61, marking a decrease of 2.20.
- For EV / EBITDA (X), as of Mar 25, the value is 7.87. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 7.87, marking a decrease of 1.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 24.85. This value exceeds the healthy maximum of 3. It has decreased from 26.74 (Mar 24) to 24.85, marking a decrease of 1.89.
- For Price / BV (X), as of Mar 25, the value is 1.97. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.97, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 24.87. This value exceeds the healthy maximum of 3. It has decreased from 26.75 (Mar 24) to 24.87, marking a decrease of 1.88.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Emmessar Biotech & Nutrition Ltd:
- Net Profit Margin: 51.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.96% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.1% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 528
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 15.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 58 (Industry average Stock P/E: 114.26)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 51.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Others | Plot No.T-3/2, Raigad District Maharashtra 410208 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Srinivasa Raghavan Mathurakavi Ayyangar | Managing Director |
| Mr. Jeyavel B Nadar | Executive Director |
| Dr.(Mrs.) Sarada S Raghavan | Non Executive Director |
| Dr.(Mrs.) Anuradha S Raghavan | Non Executive Director |
| Mr. Milind Sitaram Desai | Ind. Non-Executive Director |
| Mr. Veeraraghavan Ranganathan | Ind. Non-Executive Director |
| Mr. Dinesh Kumar Deora | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd's intrinsic value (as of 04 February 2026) is ₹27.65 which is 3.56% higher the current market price of ₹26.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹13.3 Cr. market cap, FY2025-2026 high/low of ₹42.9/24.3, reserves of ₹3.00 Cr, and liabilities of ₹9.52 Cr.
What is the Market Cap of Emmessar Biotech & Nutrition Ltd?
The Market Cap of Emmessar Biotech & Nutrition Ltd is 13.3 Cr..
What is the current Stock Price of Emmessar Biotech & Nutrition Ltd as on 04 February 2026?
The current stock price of Emmessar Biotech & Nutrition Ltd as on 04 February 2026 is ₹26.7.
What is the High / Low of Emmessar Biotech & Nutrition Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Emmessar Biotech & Nutrition Ltd stocks is ₹42.9/24.3.
What is the Stock P/E of Emmessar Biotech & Nutrition Ltd?
The Stock P/E of Emmessar Biotech & Nutrition Ltd is 58.0.
What is the Book Value of Emmessar Biotech & Nutrition Ltd?
The Book Value of Emmessar Biotech & Nutrition Ltd is 16.0.
What is the Dividend Yield of Emmessar Biotech & Nutrition Ltd?
The Dividend Yield of Emmessar Biotech & Nutrition Ltd is 0.00 %.
What is the ROCE of Emmessar Biotech & Nutrition Ltd?
The ROCE of Emmessar Biotech & Nutrition Ltd is 12.6 %.
What is the ROE of Emmessar Biotech & Nutrition Ltd?
The ROE of Emmessar Biotech & Nutrition Ltd is 4.23 %.
What is the Face Value of Emmessar Biotech & Nutrition Ltd?
The Face Value of Emmessar Biotech & Nutrition Ltd is 10.0.